Abstract
Sodium retention and volume overload are main determinants of poor response to RAAS inhibition in patients with diabetes. As volume excess can exist without symptoms, biomarkers are needed to identify a priori which patients are volume overloaded and may experience less benefit from RAAS inhibition. N-terminal pro-brain natriuretic peptide (NT-proBNP) is released in the setting of increased cardiac wall stress and volume overload. We conducted a post-hoc analysis among 5081 patients with type 2 diabetes mellitus participating in the ALTITUDE trial to investigate whether NTproBNP can predict the effects of additional therapy with aliskiren on cardio-renal endpoints. Aliskiren compared to placebo reduced the risk of the primary cardio-renal endpoint events by 20% (95%CI: 16 to 61) and 2% (-42 to 30) in the two lowest NT-proBNP tertiles, and it increased the risk by 25% (-4 to 96) in the highest NT-proBNP tertile (p-value for trend = 0.009). Similar trends were observed for the cardiovascular and ESRD end points. Effects of aliskiren compared to placebo on safety outcomes (hyperkalemia and hospitalization for acute kidney injury) were independent of NT-proBNP. In conclusion, baseline NT-proBNP may be used as a marker to predict the response to aliskiren on cardio-renal outcomes when added to standard therapy with RAAS inhibition. This article is protected by copyright. All rights reserved.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Diabetes, Obesity and Metabolism Online |
Vol/bind | 20 |
Udgave nummer | 12 |
Sider (fra-til) | 2899-2904 |
Antal sider | 5 |
ISSN | 1463-1326 |
DOI | |
Status | Udgivet - dec. 2018 |